Overview

Anticoagulation for Non-occlusive Portal Vein Thrombosis in Patients With Liver Cirrhosis

Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine the safety and efficacy of anticoagulation in the treatment of non-occlusive portal vein thrombosis in patients with liver cirrhosis.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Air Force Military Medical University, China
Fourth Military Medical University
Treatments:
Calcium
Calcium, Dietary
Nadroparin
Warfarin
Criteria
Inclusion Criteria:

- Informed consent was obtained

- liver cirrhosis

- Non-occlusive portal vein thrombosis

- No history of variceal bleeding or receive endoscopy or β-blocker for the prevention
of patients with G3 or G2 with red marks within 3 months before enrollment

- No plan for liver transplantation

- Age between 18 and 70

- Child-Pugh score ≤ 11

Exclusion Criteria:

- Acute PVT

- Fibrotic cord of PV

- Isolated splenic vein thrombosis or isolated superior mesenteric vein thrombosis

- Extensive superior mesenteric vein thrombosis involving the distal part

- Known coagulation disorder besides liver cirrhosis

- HCC or other malignant tumor

- Patients with G2 varices with red mark or G3 but did not underwent any preventive
endoscopy or β-blockers

- Platelet count < 10×109/L

- Receive contraceptive, anticoagulation or antiplatelet drug

- Receiving thrombolysis treatment

- Receiving TIPS or shunting surgery

- Bleeding tendency

- Recent gastrointestinal bleeding like digestive ulcer or hemorrhagic stroke

- Severe portal hypertension,for example, refractory ascite or acute variceal bleeidng

- Spontaneous bacterial peritonitis

- Severe cardiovascular disorder, endocrine disorder, or mental disease

- Major surgery within 6 months

- History of organ transplantation

- Pregnancy or breast-feeding

- History of HIV

- Poor compliance